Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial

NCT04832607 is registered in ClinicalTrials.gov with Tobias Feuchtinger as lead sponsor.

NCT NCT04832607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04832607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial
Lead sponsor
Tobias Feuchtinger
Phase
Phase 3
Overall status
Recruiting
Start date
August 27, 2019
Completion date
September 30, 2028
Enrollment
149 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

adv infection, cmv infection, ebv infection, stem cell transplant complications